Align Technology Launches Align X-ray Insights, an AI Computer-Aided Detection Software, in the European Union and United Kingdom
The Solution to be Showcased at 2025 IDS Dental Show in Cologne, Germany
Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the launch in European Union countries and the United Kingdom of Align X-ray Insights, a new software-based (CADe*) computer aided detection solution that uses artificial intelligence (AI) to automatically analyze 2D radiographs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310448632/en/
Align X-ray Insights, an AI Computer-Aided Detection Software (Photo: Business Wire)
As part of the Align™ Digital Platform, Align X-ray Insights software is designed to support doctors to diagnose dental and oral health conditions, standardize analysis, streamline workflows, and improve patient engagement. A recent survey among early doctor users of the technology showed it helped 95% of them in communicating patient oral health conditions. Furthermore, 91% agreed that, when shown to patients, it improved patient trust and treatment acceptance of restorative procedures.1
After confirming diagnosis, doctors can use the Align X-ray Insights detailed report, automatic tooth charting, and color overlays of radiographic abnormalities for patient education and treatment planning. The AI detection functionalities include caries, periapical radiolucencies and periodontal bone loss and other conditions.
Align X-ray Insights – alongside Align™ Oral Health Suite, a comprehensive digital suite providing a clinical framework to empower engaging oral health conversations – further reinforces Align’s commitment to dental diagnostics by launching an X-ray diagnostic digital solution that can enhance the already available NIRI (Near Infra-Red Imaging) technology with iTero intraoral scanners and Oral Health Suite’s capabilities, with the objective to support and advance doctor treatment planning decisions and priorities, based on the patient records available.
“Align X-ray Insights represents a significant advancement in our digital restorative dentistry solutions with broader patient applicability,” said Simon Beard, Align Technology executive vice president and managing director, Europe, Middle East, and Africa (EMEA). “By integrating AI into radiographic analysis, we are empowering doctors with more precise diagnostic capabilities to improve their patient outcomes. This launch underscores our commitment to innovation and our ongoing efforts to expand our digital platform.”
“It is fantastic to see Align X-ray Insights being integrated into Align’s digital platform – bringing diagnostic AI capabilities to dentists all over the world. When we started our journey towards AI in dental diagnostics, we had hoped to improve patient outcomes via better diagnostics and treatment decisions,” said Professor Falk Schwendicke, director of the Dental Clinic at University of Munich. “Since then, we learned that further value lies in Align X-ray Insights by fostering patient communication, and facilitating comprehensive, systematic reporting. Combining this with the products and services already available to Align users is a leap forward for digital dentistry.”
Align Technology acquired dentalXrai GmbH in 2022 and has since worked on integrating its flagship product into the Align Digital Platform. Align X-ray Insights, a cloud-based software, can be accessed either from any desktop or tablet or through an integration with iTero. The desktop / tablet version becomes generally available in the European Union and United Kingdom as of March 25, 2025, and will be presented at the IDS tradeshow in Cologne, Germany on March 25-29, 2025. The integration of Align X-ray Insights with iTero™ intraoral scanners is underway and will commence limited market release soon. Align X-ray Insights received regulatory clearance in Europe, the UK, Canada and New Zealand, with further availability in other countries planned, pending approvals such as 510K clearance in the United States of America.
For more information, interested customers can visit www.alignxrayinsights.com. As part of the launch offer, doctors can benefit from a 60-day free-trial.
*CADe = computer-aided detection
- Based on a survey of n=24 doctors (19 GP / 5 orthodontists) using Align™ X-ray Insights in Europe (FR, UK, IT, DE, ES, NL, DK and LV) who were part of a limited market release. Doctors indicated their agreement with different statements using a 4-point scale from strongly agree to strongly disagree. Statements included “Align X-ray Insights, when shown to patients, increased treatment acceptance of restorative procedures.” (91% agreement), “Align X-ray Insights streamlines the dental diagnostic workflow, helping me save valuable time.” (70% agreement), “Align X-ray Insights contributes to higher trust when shown to patients during treatment option discussions.” (91% agreement) and “Align X-ray Insights helps me communicate patient oral health conditions and treatment options.” (95% agreement). Align X-ray Insights is intended to be used in conjunction with an evaluation by the doctor and should not be solely relied upon to make or confirm a diagnosis. Data on file at Align Technology as of January 2025.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 271.6 thousand doctor customers and is key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat approximately 19.5 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, and Align Digital Platform are trademarks of Align Technology, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310448632/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom